Beacon Financial Group Acquires 195 Shares of Novo Nordisk A/S (NYSE:NVO)

Beacon Financial Group boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 7.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,707 shares of the company’s stock after buying an additional 195 shares during the period. Beacon Financial Group’s holdings in Novo Nordisk A/S were worth $233,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NVO. Warther Private Wealth LLC lifted its stake in shares of Novo Nordisk A/S by 14.2% in the 4th quarter. Warther Private Wealth LLC now owns 12,021 shares of the company’s stock valued at $1,034,000 after purchasing an additional 1,497 shares during the period. Leavell Investment Management Inc. increased its holdings in Novo Nordisk A/S by 13.6% in the fourth quarter. Leavell Investment Management Inc. now owns 3,968 shares of the company’s stock valued at $341,000 after purchasing an additional 475 shares during the last quarter. Portfolio Design Labs LLC bought a new stake in Novo Nordisk A/S in the fourth quarter valued at about $208,000. Augustine Asset Management Inc. acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $1,693,000. Finally, Quent Capital LLC bought a new position in Novo Nordisk A/S during the fourth quarter worth about $62,000. 11.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday. They set an “equal weight” rating on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Down 2.3 %

Shares of NVO stock opened at $81.78 on Thursday. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a fifty day moving average of $90.45 and a 200-day moving average of $110.60. The company has a market capitalization of $366.99 billion, a price-to-earnings ratio of 24.86, a P/E/G ratio of 0.96 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities research analysts predict that Novo Nordisk A/S will post 3.86 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a $0.7874 dividend. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s payout ratio is presently 21.88%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.